Growing Glioblastoma Multiforme Treatment Market: Insights & Forecasts for 2025-2033

Growing Glioblastoma Multiforme Treatment Market: Insights & Forecasts for 2025-2033

November 25, 2024 Catherine Williams - Chief Editor Health

Glioblastoma Multiforme Treatment Market Overview

Ottawa, Nov. 25, 2024 (GLOBE NEWSWIRE) – The glioblastoma multiforme (GBM) treatment market is projected to grow from USD 3.01 billion in 2025 to approximately USD 5.68 billion by 2033, according to Precedence Research. In North America, the market size for GBM treatment reached USD 2.06 billion in 2023.

Key Facts About Glioblastoma

  • GBM is the most common and aggressive type of glioma, making up 45.2% of primary malignant brain tumors.
  • It accounts for over 50% of all malignant primary CNS tumors and around 15% of all primary CNS tumors.
  • The annual incidence of GBM is approximately 35 cases per million people, with a male-to-female ratio of 1.6:1.
  • Treatment typically involves a multidisciplinary approach, including surgery followed by adjuvant radiochemotherapy.

Current Treatment Methods

  • Vaccines: Tumor and dendritic cell-based cancer vaccines represent 51% of treatment options. Currently, 7% are in phase 3 trials, while 51% are in phase 1 studies. For recurrent GBM, targeted therapies make up 55%.
  • Surgery: This remains the largest treatment segment, holding a market share of 33.10% in 2023.
  • Radiation Therapy: Anticipated to grow significantly in the coming years due to its effectiveness in managing GBM.

Regional Insights

  • North America leads the GBM treatment market, accounting for 42.42% market share in 2023.
  • The Asia-Pacific region is expected to exhibit strong growth due to increased R&D efforts and a growing patient base.

Market Growth Factors

  • Advancements in immunotherapy and vaccine development are paving the way for innovative treatment options.
  • Increased government funding and high R&D investments in North America contribute to market expansion.

Future Prospects

  • The U.S. GBM treatment market size is expected to reach USD 1,442.86 million by 2033, growing at a CAGR of 7.80% from 2024 to 2033.
  • The evolving landscape indicates a growing focus on personalized treatments and non-invasive procedures like Tumor Treating Field (TTF) therapy.

Leading Companies in the Market

  • Major players in the GBM treatment market include:
    • Merck & Co., Inc.
    • Amgen, Inc.
    • F. Hoffmann-La Roche Ltd.
    • Pfizer Inc.
    • Teva Pharmaceutical Industries Ltd.

Conclusion

The glioblastoma multiforme treatment market is on a growth trajectory supported by advancements in medical research and technology. Continued innovation and increased investment in treatment options will likely improve patient outcomes in the coming years. Emphasis on personalized and non-invasive therapies will shape the future of GBM management.